EUVIMEDTutustu EUVIMEDiin
EUVIMED · CrossrefJournal

Journal of Experimental & Clinical Cancer Research

ISSN 1756-9966 · Springer Science and Business Media LLC

Latest articles

  1. Comprehensive characterization of bone marrow remodeling in lung cancer identifies tasquinimod as a potential adjuvant to anti-PD-L1 immunotherapy

    Evelyn Calderon-Espinosa, Kirsten De Ridder, Mekhin Carpentier, Hatice Satilmis, Tessa De Pauw, Sam Floru, Tim Dreessen, Daliya Kancheva, Isabelle Scheyltjens, Katrien Vandoorne, Kathleen Van den Eynde, Lieven P. Depypere, Paul De Leyn, Sophie Hernot, Kim De Veirman, Kiavash Movahedi, Yanina Jansen, Cleo Goyvaerts

    Published: 2026-11-19DOI: 10.1186/s13046-026-03872-7

  2. Preclinical trial supports dual inhibition of BCL2 and Aurora kinase A for high-risk neuroblastoma

    Alvin Kamili, Brandon A. Hearn, Isabella Temelkoska, Joan Solomon, Madeleine S. Wheatley, Christina H. T. Bui, Caroline J. Atkinson, Leith-Justin Elhassadi, Sadia Qureshi, Jayne Murray, Roxanne Cadiz, Andrew J. Gifford, Louise Cui, Lewis Crowley, Angela Lin, Chelsea Mayoh, Marie Wong-Erasmus, Timothy W. Failes, Greg M. Arndt, Michelle Haber, Murray D. Norris, M. Emmy M. Dolman, Toby N. Trahair, Jamie I. Fletcher

    Published: 2026-11-18DOI: 10.1186/s13046-026-03875-4

  3. Correction: Carboxylesterase 1 is a core metabolic vulnerability of platinum-resistant high-grade serous ovarian carcinoma

    Irene Flati, Davide Vecchiotti, Fiorenza Di Giovanni, Daniela Verzella, Francesca Dall’Aglio, Angelo Sarra, Chiara Battistini, Melissa Zambuto, Giuseppe Frisullo, Jessica Cornice, Ilaria Nunzi, Mauro Di Vito Nolfi, Harry J. Whitwell, Francesca Veglianti, Hafiz Nadeem Khan, Saverio Marchi, Guido Franzoso, Ugo Cavallaro, Daniel D’Andrea, Edoardo Alesse, Francesca Zazzeroni, Daria Capece

    Published: 2026-11-10DOI: 10.1186/s13046-026-03863-8

  4. Correction: Targeting the CAF-GDF15 axis attenuates AKT-mediated mitochondrial rewiring and chemoradiation resistance in esophageal adenocarcinoma

    Ningbo Fan, Pinwei Deng, Zhefang Wang, Feng Ju, Lisa Raatz, Oscar Velazquez Camacho, Axel M. Hillmer, Margarete Odenthal, Phuong-Hien Nguyen, Zicheng Lyu, Felix Popp, Seung-Hun Chon, Maarten F. Bijlsma, Romy Ros, Hanneke W. M. van Laarhoven, Alexander Quaas, Jörg Wischhusen, Yue Zhao, Christiane J. Bruns

    Published: 2026-11-06DOI: 10.1186/s13046-026-03859-4

  5. Targeting the splicing factor RBM39 reduces mitotic fidelity and enhances taxane cytotoxicity in triple negative breast cancer cells

    Vanessa Medici, Cinzia Caggiano, Ludovica Altieri, Claudia Mancini, Alessandra Ciucci, Eleonora Kristina Scarpone, Claudia Landolfo, Mohammad Salik Zeya Ansari, Eleonora Cesari, Giacomo Milletti, Emanuele Panatta, Alba Di Leone, Alessandra Fabi, Riccardo Masetti, Pierre de la Grange, Daniela Trisciuoglio, Patrizia Lavia, Claudio Sette, Chiara Naro

    Published: 2026-11-06DOI: 10.1186/s13046-026-03868-3

  6. Correction: Suppression of Spry1 reduces HIF1α‑dependent glycolysis and impairs angiogenesis in BRAF‑mutant cutaneous melanoma

    Barbara Montico, Giorgio Giurato, Roberto Guerrieri, Francesca Colizzi, Annamaria Salvati, Giovanni Nassa, Jessica Lamberti, Domenico Memoli, Patrizia Sabatelli, Marina Comelli, Arianna Bellazzo, Albina Fejza, Lucrezia Camicia, Lorena Baboci, Michele Dal Bo, Alessia Covre, Tuula A. Nyman, Alessandro Weisz, Agostino Steffan, Michele Maio, Luca Sigalotti, Maurizio Mongiat, Eva Andreuzzi, Elisabetta Fratta

    Published: 2026-08-21DOI: 10.1186/s13046-026-03800-9

  7. Correction: JAK/STAT3 represents a therapeutic target for colorectal cancer patients with stromal‑rich

    Kathryn A. F. Pennel, Phimmada Hatthakarnkul, Colin S. Wood, Guang‑Yu Lian, Sara S. F. Al‑Badran, Jean A. Quinn, Assya Legrini, Jitwadee Inthagard, Peter G. Alexander, Hester van Wyk, Ahmad Kurniawan, Umar Hashmi, Michael A. Gillespie, Megan Mills, Aula Ammar, Jennifer Hay, Ditte Andersen, Colin Nixon, Selma Rebus, David K. Chang, Caroline Kelly, Andrea Harkin, Janet Graham, David Church, Ian Tomlinson, Mark Saunders, Tim Iveson, Tamsin R. M. Lannagan, Rene Jackstadt, Noori Maka, Paul G. Horgan, Campbell S. D. Roxburgh, Owen J. Sansom, Donald C. McMillan, Colin W. Steele, Nigel B. Jamieson, James H. Park, Antonia K. Roseweir, Joanne Edwards

    Published: 2026-08-15DOI: 10.1186/s13046-026-03811-6

  8. Development of a cell-penetrating peptide for intracellular delivery of a biologically active HPV E6 inhibitor in cervical cancer cells

    Luisa Dassi, Anna Lucia Tornesello, Marian Vincenzi, Marilisa Leone, Vincenzo Ingangi, Wuyuan Lu, Andrea Cerasuolo, Tiziana Pecchillo Cimmino, Sara Amiranda, Mariapia Napolitano, Palma Tirino, Franca Maria Tuccillo, Luigi Buonaguro, Vincenza De Gregorio, Giorgia Imparato, Franco Maria Buonaguro, Maria Lina Tornesello

    Published: 2026-08-12DOI: 10.1186/s13046-026-03805-4

  9. Therapeutic NAMPT inhibition reveals a targetable metabolic vulnerability in neuroblastoma

    Sophia Varriano, Amy Yu, Abantika Chakraborty, Ariana E. Nelson, Amy James, Kristine Isanogle, Nimit Patel, Caleb Kim, Unsun Lee, Victor J. Collins, Grace B. McKay-Corkum, Ye Yang, Xiaohu Zhang, Crystal McKnight, Kelli Wilson, Carleen Klumpp-Thomas, Michele Ceribelli, David Holland, Ming Sun, Gitanjali Asampille, Ying Wu, Krithika Bhuvaneshwar, Brad Gouker, Donna Butcher, Bhushan L. Thakur, Arnulfo Mendoza, Sameer H. Issaq, Mirit I. Aladjem, Baktiar O. Karim, Jack F. Shern, Parthav Jailwala, Simone Difilippantonio, Craig J. Thomas, Daniel R. Crooks, Rosa Nguyen, Carol J. Thiele, Christine M. Heske

    Published: 2026-08-05DOI: 10.1186/s13046-026-03793-5

Volumes

2026 · 2602025 · 3612024 · 3352023 · 3472022 · 3642021 · 4042020 · 2872019 · 5062018 · 3272017 · 1942016 · 1932015 · 1592014 · 1592013 · 1062012 · 1042011 · 1172010 · 1752009 · 1602008 · 88

Työhösi sopivaa tietoa.

Maksuttomasta aloituksesta ja henkilökohtaisesta kirjallisuushausta koko Research Suite -kokonaisuuteen.

Katso hinnat →

Sisältyvätkö kaikki kustantajien kokotekstit?

Ei. Bibliografiset viitteet, tiivistelmät ja kokotekstit ovat eri sisältöjä. Se, onko kokoteksti saatavilla, riippuu lähteestä, Open Accessista ja olemassa olevista lisensseistäsi. EUVIMED-paketti ei korvaa ylimääräisiä kustantajaoikeuksia.